Latest Zika Virus Updates from CDC and NIAID

The Centers for Disease Control and Prevention and the National Institute of Allergy and Infectious Diseases will hold a media telebriefing to provide updated information on the Zika virus outbreak, focusing on current understanding of transmission, clinical effects, and public health guidance.

The briefing, scheduled for January 27, 2016, at 4:00 p.m. Eastern Time, will feature experts from both agencies discussing the latest developments in the ongoing investigation into Zika virus, particularly its association with birth defects such as microcephaly and neurological complications like Guillain-Barré syndrome.

Zika virus, primarily transmitted through the bite of infected Aedes species mosquitoes, has been identified in multiple countries across the Americas, prompting heightened concern due to its suspected link to congenital abnormalities in infants born to infected mothers. The CDC and NIAID are coordinating research efforts to better understand the virus’s pathogenesis, evaluate diagnostic tools, and assess potential vaccine candidates.

Public health officials emphasize that while many Zika infections are asymptomatic or cause only mild symptoms such as fever, rash, joint pain, and conjunctivitis, the potential risks to fetal development have prompted travel advisories and enhanced surveillance in affected regions. The telebriefing aims to clarify current knowledge gaps and outline ongoing prevention strategies, including mosquito control measures and guidance for pregnant women and those planning pregnancy.

Research into Zika virus has accelerated since the outbreak gained international attention, with scientists working to isolate viral strains, study immune responses, and develop reliable laboratory tests. The NIAID, as part of the National Institutes of Health, is supporting preclinical and early-stage clinical research on vaccine platforms, while the CDC continues to lead outbreak response, case tracking, and public communication efforts.

As of early 2016, no licensed vaccine or specific antiviral treatment for Zika virus exists, and management remains focused on symptom relief and preventive measures. Health authorities continue to recommend that individuals, especially pregnant women, avoid travel to areas with active Zika transmission when possible and take steps to prevent mosquito bites through the use of insect repellent, protective clothing, and environmental controls.

The telebriefing will provide an opportunity for journalists and public health stakeholders to receive direct updates from federal experts and to ask questions about the evolving situation. Information shared during the briefing is intended to support accurate reporting and informed public health decision-making at the local, state, and national levels.